Cargando…

Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study

BACKGROUND: Improvement in acromegaly management increased disease survival and prevalence. Evidence regarding acromegaly in older adults are sparse. We aim to explore acromegaly impact on aging process quality. METHODS: Multicenter case-control study conducted on 42 older adults (≥ 65 years) acrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gagliardi, Irene, Chiloiro, Sabrina, Vallillo, Maria, Bondanelli, Marta, Volpato, Stefano, Giampietro, Antonella, Bianchi, Antonio, De Marinis, Laura, Zatelli, Maria Chiara, Ambrosio, Maria Rosaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547074/ https://www.ncbi.nlm.nih.gov/pubmed/34702173 http://dx.doi.org/10.1186/s12877-021-02549-4

Ejemplares similares

Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience
por: Chiloiro, Sabrina, et al.
Publicado: (2022)

Long-term low-dose tolvaptan efficacy and safety in SIADH
por: Bondanelli, Marta, et al.
Publicado: (2023)

Hypeprolactinemia: still an insidious diagnosis
por: Aliberti, Ludovica, et al.
Publicado: (2020)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Glucose Metabolism Derangements and Thyroid Nodules: Does Sex Matter?
por: Gobbo, Alberto, et al.
Publicado: (2022)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Beta‐thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria
por: Aliberti, Ludovica, et al.
Publicado: (2022)

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly
por: Chiloiro, Sabrina, et al.
Publicado: (2022)

Evaluation of a Nep-Score Threshold and the Derived Nep-D Score in Predicting Survival of Patients With Typical and Atypical Bronchial Carcinoids
por: Gagliardi, Irene, et al.
Publicado: (2021)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

THU055 The Acro-TIME Score: A New Clinical, Pathological And Immune Integrative Approach To Early Identify Acromegaly Patients Resistant To Treatment With First Generation Somatostatin Ligands
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

Gastrointestinal carcinoma first presenting as pituitary mass: recognition of a rare case and multidisciplinary approach for the management of pituitary metastases
por: Costanza, Flavia, et al.
Publicado: (2023)

Is the ghost of brown tumor back again? Features of hypercalcaemic primary hyperparathyroidism we must not forget
por: Gagliardi, Irene, et al.
Publicado: (2021)

Role of Pituitary Tumour Transforming Gene 1 in Medullary Thyroid Carcinoma
por: Zatelli, Maria Chiara, et al.
Publicado: (2010)

Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life
por: Cangiano, Biagio, et al.
Publicado: (2022)

Investigation of COVID-19 infection in subjects with Klinefelter syndrome
por: Aliberti, L., et al.
Publicado: (2022)

Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line
por: Gentilin, E., et al.
Publicado: (2023)

Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study
por: Bima, Chiara, et al.
Publicado: (2021)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience
por: Gagliardi, Irene, et al.
Publicado: (2022)

The role of opportunistic quantitative computed tomography in the evaluation of bone disease and risk of fracture in thalassemia major
por: Carnevale, Aldo, et al.
Publicado: (2022)

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
por: Urso, Luca, et al.
Publicado: (2022)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors
por: Mattogno, Pier Paolo, et al.
Publicado: (2021)

SUN-LB076 Potential Role of Gallium-68-Peptides and Fluorine-18-FDG PET/CT and Ki67 in Patients with Post-Surgical Residual Pituitary Adenoma
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

NEP-Score Thresholds Predict Survival of Patients With Bronchial Carcinoids
por: Gagliardi, Irene, et al.
Publicado: (2021)

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
por: Iacovazzo, Donato, et al.
Publicado: (2019)

Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review
por: Menotti, Sara, et al.
Publicado: (2023)

The immune microenviroment in somatotropinomas: from biology to personalized and target therapy
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case
por: Costanza, Flavia, et al.
Publicado: (2023)

Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
por: Chiloiro, Sabrina, et al.
Publicado: (2023)

THU093 Pituitary Enlargement And Hypopituitarism In Patients Treated With Immune Checkpoint Inhibitors: Two Sides Of The Same Coin?
por: Menotti, Sara, et al.
Publicado: (2023)

Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

New Variations on the Theme of Multidimensional Geriatric Assessment
por: Wieland, G. Darryl
Publicado: (2020)

Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors
por: Bianchi, Antonio, et al.
Publicado: (2023)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Cyclo-Oxygenase 2 Modulates Chemoresistance in Breast Cancer Cells Involving NF-κB
por: Zatelli, Maria Chiara, et al.
Publicado: (2009)

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
por: Bianchi, Antonio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_73k0scukjomg9hi43mhoghqfev